The DOI matches its Crossref record.
A target‐mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans
Abstract
Background: The Vascular Endothelial Growth Factor (VEGF) in Ischemiafor Vascular Angiogenesis (VIVA) trial was a double‐blind, placebo‐controlled, phase II clinical trial designed to evaluate the safety, efficacy, and pharmacokinetics of combinedintracoronary and intravenous infusions of recombinant human vascular endothelial growth factor (rhVEGF 165) for therapeutic angiogenesis. This study describes the use of a mechanism‐based model to characterize the nonlinear kinetics observed after intravenous administration of rhVEGF 165. The model predicts that rhVEGF 165 distribution occurs through both saturable binding to high‐affinity receptors and reversible interactions with low‐affinity binding sites. Methods: In this trial, rhVEGF 165 was administered to patients with coronary artery disease at a dose rate of 17 or 50 ng/kg/min by means of intracoronary infusion for 20 minutes, followed by three 4‐hour intravenous infusions on days 3, 6, and 9. Pharmacokinetic samples and blood pressure measurements were collected at baseline, during infusion, and for 6 hours after infusion. Results: The plasma clearance, steady‐state volume of distribution, and terminal half‐life after a 4‐hour intravenous infusion of rhVEGF 165 at the high dose were 19.1 ± 5.7 mL/min/kg, 960 ± 260 mL/kg, and 33.7 ± 13 minutes, respectively. The duration of hypotension that occurred after rhVEGF 165 administration appeared to be related to the model‐predicted VEGF 165 concentration associated with the high‐affinity receptor compartment. Conclusions: This mechanism‐based model accurately predicted VEGF concentrations and allowed for the simulation of various rhVEGF 165 dose regimens that may aid in optimization of drug delivery for future clinical trials. Clinical Pharmacology & Therapeutics (2002) 72, 20–32; doi: 10.1067/mcp.2002.126179
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Lee, K., Silva, E. A., & Mooney, D. J. (2011) · Journal of The Royal Society Interface · doi:10.1098/rsif.2010.0223 · Cited by 1,386
Toward delivery of multiple growth factors in tissue engineering
Chen, F.-M., Zhang, M., & Wu, Z.-F. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.04.053 · Cited by 649
Zangi, L., Lui, K. O., von Gise, A., Ma, Q., Ebina, W., Ptaszek, L. M., Später, D., Xu, H., Tabebordbar, M., Gorbatov, R., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2682 · Cited by 646
Systemic delivery of genes to striated muscles using adeno-associated viral vectors
Gregorevic, P., Blankinship, M. J., Allen, J. M., Crawford, R. W., Meuse, L., Miller, D. G., Russell, D. W., & Chamberlain, J. S. (2004) · Nature Medicine · doi:10.1038/nm1085 · Cited by 620
Ren, X., Feng, Y., Guo, J., Wang, H., Li, Q., Yang, J., Hao, X., Lv, J., Ma, N., & Li, W. (2015) · Chemical Society Reviews · doi:10.1039/c4cs00483c · Cited by 573
Metadata
- Authors
- Eppler, S. M., Combs, D. L., Henry, T. D., Lopez, J. J., Ellis, S. G., Yi, J., Annex, B. H., McCluskey, E. R., & Zioncheck, T. F.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2002-07
- Volume
- 72
- Issue
- 1
- Pages
- 20-32
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W1994322982
- Cited by
- 266
- References
- 0
- FWCI
- 2.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A target‐mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. https://app.cochat.ai/papers/10.1067/mcp.2002.126179
- The paper
- Eppler, S. M., Combs, D. L., Henry, T. D., Lopez, J. J., Ellis, S. G., Yi, J., Annex, B. H., McCluskey, E. R., & Zioncheck, T. F. (2002). A target‐mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clinical Pharmacology & Therapeutics. https://doi.org/10.1067/mcp.2002.126179
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.